Clinical Trial Details
| Trial ID: | L0803 |
| Source ID: | JPRN-UMIN000030498 |
| Associated Drug: | Dapagliflozin |
| Title: | |
| Acronym: | -- |
| Status: | Recruiting |
| Study Results: | No Results Available |
| Results: | -- |
| Conditions: | Type 2 diabetes mellitus |
| Interventions: | Orally administration of 5mg Dapagliflozin once a day for 24weeks. |
| Outcome Measures: | Evaluation of the change of hepatic lipid content measured by MRS at 24 weeks after starting<br> trial.Evaluation of the change of blood and urine examination at 4,12, and 24 weeks after starting<br> trial. <br>Evaluation of the change of microbiota at 24 weeks after starting trial. <br>Evaluation of the change of body composition<br> measured by InBody at 12 and 24 weeks after starting trial. <br>Evaluation of the change of CAP and LSM measured by Fibroscan at 12 and 24 weeks after starting trial. |
| Sponsor/Collaborators: | Tokai University |
| Gender: | All |
| Age: | 20years-old80years-old |
| Phases: | Not selected |
| Enrollment: | 30 |
| Study Type: | Interventional |
| Study Designs: | Single arm Non-randomized |
| Start Date: | 20/12/2017 |
| Completion Date: | -- |
| Results First Posted: | -- |
| Last Update Posted: | 2 April 2019 |
| Locations: | Japan |
| URL: | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034810 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D101 | Dapagliflozin | Chemical drug | DB06292 | SLC5A2 antagonist; SLC5A2 inhibitor | Antidiabetic drug | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |